Unicycive Therapeutics Investors Face November Deadline in Fraud Suit

The lawsuit centers on claims that Unicycive Therapeutics misled shareholders by withholding critical information about its third-party manufacturing vendor. According to the complaint, the company failed to audit the vendor’s facility for compliance with current good manufacturing practices, leaving management without a reasonable basis to claim that previous FDA deficiencies had been resolved. This oversight allegedly created an undisclosed risk that the FDA would demand further information, ultimately jeopardizing the timely regulatory approval of OLC.

By failing to disclose these operational vulnerabilities, company leadership allegedly issued materially misleading statements regarding the firm's business prospects. Shareholders who purchased stock during the relevant period may participate in the class action, though they remain free to retain independent counsel or choose not to take action at this time. Those interested in pursuing the case are encouraged to contact the Law Offices of Frank R. Cruz before the November deadline to confirm their eligibility as lead plaintiffs.